Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Pedro R. Lowenstein"'
Autor:
Mahmoud S. Alghamri, Brandon L. McClellan, Carson S. Hartlage, Santiago Haase, Syed Mohd Faisal, Rohit Thalla, Ali Dabaja, Kaushik Banerjee, Stephen V. Carney, Anzar A. Mujeeb, Michael R. Olin, James J. Moon, Anna Schwendeman, Pedro R. Lowenstein, Maria G. Castro
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Gliomas are one of the most lethal types of cancers accounting for ∼80% of all central nervous system (CNS) primary malignancies. Among gliomas, glioblastomas (GBM) are the most aggressive, characterized by a median patient survival of fewer than 1
Externí odkaz:
https://doaj.org/article/d0bcbb33bc1e4b30b99e75b5f849bf8c
Autor:
Mahmoud S. Alghamri, Kaushik Banerjee, Anzar A. Mujeeb, Ava Mauser, Ayman Taher, Rohit Thalla, Brandon L. McClellan, Maria L. Varela, Svetlana M. Stamatovic, Gabriela Martinez-Revollar, Anuska V. Andjelkovic, Jason V. Gregory, Padma Kadiyala, Alexandra Calinescu, Jennifer A. Jiménez, April A. Apfelbaum, Elizabeth R. Lawlor, Stephen Carney, Andrea Comba, Syed Mohd Faisal, Marcus Barissi, Marta B. Edwards, Henry Appelman, Yilun Sun, Jingyao Gan, Rose Ackermann, Anna Schwendeman, Marianela Candolfi, Michael R. Olin, Joerg Lahann, Pedro R. Lowenstein, Maria G. Castro
Publikováno v:
ACS Nano
Glioblastoma (GBM) is an aggressive primary brain cancer; with a 5-year survival of ~5%. Challenges that hamper GBM therapeutic efficacy include: (i) tumor heterogeneity, (ii) treatment resistance, (iii) immunosuppressive tumor microenvironment (TME)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b753af4faafaed24e5ea318bc7ec661b
https://europepmc.org/articles/PMC9649873/
https://europepmc.org/articles/PMC9649873/
Autor:
Santiago Haase, Jessica C. Gauss, Stephen Carney, Maria G. Castro, Felipe J Nunez, Sheeba Pawar, Ramya Ravindran, Maria B. Garcia-Fabiani, Marta Edwards, Fernando M. Nunez, Padma Kadiyala, Pedro R. Lowenstein, Flor M. Mendez
Publikováno v:
Clin Cancer Res
Purpose: Diffuse intrinsic pontine glioma (DIPG) bears a dismal prognosis. A genetically engineered brainstem glioma model harboring the recurrent DIPG mutation, Activin A receptor type I (ACVR1)-G328V (mACVR1), was developed for testing an immune-st
Autor:
Alexandra Calinescu, Rohit Thalla, Mahmoud S. Alghamri, Jennifer A. Jiménez, Maria Luisa Varela, Marta Edwards, Jason V. Gregory, Marcus Barissi, Padma Kadiyala, April A. Apfelbaum, Gabriela Martinez-Revollar, Pedro R. Lowenstein, Andrea Comba, Stephen Carney, Anzar A. Mujeeb, Maria G. Castro, Joerg Lahann, Svetlana M. Stamatovic, Ayman Taher, Brandon L. McClellan, Michael R. Olin, Syed M Faisal, Anuska Andjelkovic-Zochowska, Kaushik Banerjee, Elizabeth R Lawlor, Henry D. Appelman
Glioblastoma multiforme (GBM) is an aggressive primary brain tumor, with poor prognosis. Major obstacles hampering effective therapeutic response in GBM are tumor heterogeneity, high infiltration of immunosuppressive myeloid cells, and the presence o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30efcd31438b70159553640e479fe886
https://doi.org/10.1101/2021.08.27.457953
https://doi.org/10.1101/2021.08.27.457953
Autor:
Kaushik Banerjee, Felipe J. Núñez, Santiago Haase, Brandon L. McClellan, Syed M. Faisal, Stephen V. Carney, Jin Yu, Mahmoud S. Alghamri, Antonela S. Asad, Alejandro J. Nicola Candia, Maria Luisa Varela, Marianela Candolfi, Pedro R. Lowenstein, Maria G. Castro
Publikováno v:
Frontiers in Molecular Neuroscience
Frontiers in Molecular Neuroscience, Vol 14 (2021)
Frontiers in Molecular Neuroscience, Vol 14 (2021)
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain barrier (BBB), an immunosuppressive tumor microenvironment (TME) and
Autor:
Stephen Carney, Andrea Comba, Maria B. Garcia-Fabiani, Alejandro Javier Nicola Candia, Ava Mauser, Anna Schwendeman, Maria Ventosa, Marianela Candolfi, Lindsay Scheetz, Pedro R. Lowenstein, Mahmoud S. Alghamri, Padma Kadiyala, James J. Moon, Joerg Lahann, Maria G. Castro, Syed M Faisal
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Gliomas are infiltrating brain tumors associated with high morbidity and mortality. Current standard of care includes radiation, chemotherapy and surgical resection. Today, survival rates for malignant glioma patients remain dismal and unchanged for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feb1626dafe0a01d701a6f662b67b397
https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1768528
https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1768528
Autor:
Mahmoud S. Alghamri, Felipe J Nunez, Maria G. Castro, Neha Kamran, Pedro R. Lowenstein, David Altshuler, Stephen Carney
Publikováno v:
Methods Enzymol
Glioma is one of the most aggressive tumors. The median survival of the most aggressive form (Glioblastoma (GBM)) is approximately 14–20 months. The current standard of care includes tumor resection, chemotherapy and radiation, nevertheless, the in
Publikováno v:
Clinical Immunology. 189:34-42
Various preclinical studies have demonstrated that the success of immunotherapeutic strategies in inhibiting tumor progression in animal models of Glioblastoma multiforme (GBM). It is also evident that tumor-induced immune suppression drastically imp
Autor:
Meghna Saxena, Pedro R. Lowenstein, Youping Li, Maria G. Castro, Neha Kamran, Nicholas Raja, Padma Kadiyala, Diana Shah, Mariela A. Moreno-Ayala, Marianela Candolfi
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Survival of glioma (GBM) patients treated with the current standard of care remains dismal. Immunotherapeutic approaches that harness the cytotoxic and memory potential of the host immune system have shown great benefit in other cancers. GBMs have de
High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme
Autor:
Maria G. Castro, Padma Kadiyala, Robert Doherty, Minzhi Yu, Neha Kamran, David Altshuler, Dan Li, Rui Kuai, Pedro R. Lowenstein, James J. Moon, Marta Edwards, Fernando M. Nunez, Anna Schwendeman
Publikováno v:
ACS Nano.
Glioblastoma multiforme (GBM) is an aggressive primary brain tumor, for which there is no cure. Treatment effectiveness for GBM has been limited due to tumor heterogeneity, an immunosuppressive tumor microenvironment (TME) and the presence of the blo